Histologically‐diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report

Kim, Ye Eun; Kim, Tae Min; Jo, Seong Jin

doi:10.1111/1346-8138.15091

Cited by 5 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several irAEs of special interest have been described in elderly patients treated with PD1/PD-L1 axis inhibitors and are summarized in Table 2. They included severe cutaneous adverse reactions [135][136][137][138][139][140], secondary sclerosing cholangitis [141], colangiopathy [142,143], immune-related hepatitis [144,145], type 1 diabetes [146][147][148], hypophysitis [149], primary adrenal insufficiency [150], myasthenia gravis and myopathy [151][152][153][154], myocarditis [154][155][156][157], severe heart failure [158], eosinophilic vasculitis and arteritic anterior ischemic optic neuropathy [159], blue toe syndrome due to peripheral vasculitis [160], Vogt-Koyanagi-Harada Disease-like Uveitis [161], acute interstitial nephritis [134,162], fulminant Goodpasture's disease [163], neuromyelitis optica [164], isolated optic neuritis [165], encephalitis [166], hypereosinophilia [167], severe neutropenia [144,[168][169][170], immune thrombocytopenia [171], autoimmune hemolytic anemia and hemophagocytic lymphohist...…”

Section: Case Reportsmentioning

confidence: 99%

Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review

Montrone

Rosati

Longo

et al. 2023

JCM

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, and most NSCLC is diagnosed in the advanced stage. The advent of immune check point inhibitors (ICIs) changed the therapeutic scenario both in metastatic disease (in first and subsequent lines) and earlier settings. Comorbidities, reduced organ function, cognitive deterioration, and social impairment give reasons for a greater probability of adverse events, making the treatment of elderly patients challenging. The reduced toxicity of ICIs compared to standard chemotherapy makes this approach attractive in this population. The effectiveness of ICIs varies according to age, and patients older than 75 years may benefit less than younger patients. This may be related to the so-called immunosenescence, a phenomenon that refers to the reduced activity of immunity with older age. Elders are often under-represented in clinical trials, even if they are a large part of the patients in a clinical practice. In this review, we aim to explore the biological aspects of immunosenescence and to report and analyze the most relevant and recent literature findings on the role of immunotherapy in elderly patients with NSCLC.

show abstract